Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 13,606 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatologic Disorders Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)

NCT05244980
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
TDM-105795, Placebo
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
San Diego, California • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 28, 2026, 6:26 AM EDT
Active, not recruiting No phase listed Observational

The Young Women's Breast Cancer Study

NCT01468246
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
1,302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2035
U.S. locations
12
States / cities
Aurora, Colorado • Boston, Massachusetts • Danvers, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 28, 2026, 6:26 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

NCT03958383
View directory record Official record
Conditions
Melanoma
Interventions
hu14.18-IL2, Radiation Therapy, Nivolumab, Ipilimumab
Biological · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 28, 2026, 6:26 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis

NCT05462522
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
RO7303509, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Palo Alto, California • New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 28, 2026, 6:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Topical Myristyl Nicotinate Cream on the Skin of Healthy Volunteers

NCT00619060
View directory record Official record
Conditions
Healthy
Interventions
Topical Myristyl Nicotinate Cream, Placebo
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 28, 2026, 6:26 AM EDT
Active, not recruiting Not applicable Interventional

Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey

NCT03995082
View directory record Official record
Conditions
Breast Cancer, Patient Reported Outcomes
Interventions
Patient Reported Outcome Measure Survey result feedback
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Female only
Enrollment
925 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
3
States / cities
Denver, Colorado • Highlands Ranch, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 28, 2026, 6:26 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

NCT06090266
View directory record Official record
Conditions
Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Cutaneous Melanoma, Non-small Cell Lung Cancer
Interventions
OR502, Cemiplimab
Drug
Lead sponsor
OncoResponse, Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Austin, Texas • Irving, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 28, 2026, 6:26 AM EDT
Terminated Phase 2 Interventional Results available

Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer

NCT00622466
View directory record Official record
Conditions
Breast Cancer
Interventions
paclitaxel, sorafenib tosylate
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 28, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Finasteride Treatment of Severe Nodulocystic Acne

NCT02502669
View directory record Official record
Conditions
NODULOCYSTIC ACNE
Interventions
Finasteride 23.5 mg tablets, Finasteride 33.5 mg tablets, Placebo tablets
Drug
Lead sponsor
Elorac, Inc.
Industry
Eligibility
18 Years to 35 Years · Male only
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
25
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 28, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir

NCT00031486
View directory record Official record
Conditions
Encephalitis
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Oct 28, 2026, 6:26 AM EDT
Completed No phase listed Observational

Preferences & Treatment Satisfaction Drivers in Rosacea Patients

NCT02602470
View directory record Official record
Conditions
Rosacea
Interventions
Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251), Azelaic Acid Cream, Metronidazole gel, Metronidazole cream, Metronidazole Emulsion, Metronidazole Lotion, Brimonidine Tartrate Gel
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 28, 2026, 6:26 AM EDT
Completed No phase listed Observational

A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma

NCT03696069
View directory record Official record
Conditions
Melanoma
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 28, 2026, 6:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Pilot Clinical Trial Investigating the Effect of Cutaneous Cooling on Sebum Production

NCT01686841
View directory record Official record
Conditions
Acne
Interventions
The Zeltiq System
Device
Lead sponsor
Zeltiq Aesthetics
Industry
Eligibility
18 Years to 25 Years · Male only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 28, 2026, 6:26 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis

NCT02245841
View directory record Official record
Conditions
Dermatomyositis, Juvenile Dermatomyositis
Interventions
H.P. Acthar Gel
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 28, 2026, 6:26 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT

NCT05171894
View directory record Official record
Conditions
Port-wine Birthmarks, Port-Wine Stain, Nevus Flammeus
Interventions
Hemopfin+Green Light, Vehicle+Green Light
Drug · Device
Lead sponsor
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Irvine, California • San Diego, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 28, 2026, 6:26 AM EDT
Completed Phase 1 Interventional Results available

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

NCT02222922
View directory record Official record
Conditions
Neoplasms
Interventions
PF-06647020 Q3W, fluconazole, PF-06647020 Q2W, PF-06647020 combined with Avelumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 28, 2026, 6:26 AM EDT
Completed No phase listed Observational

Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)

NCT06106282
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 28, 2026, 6:26 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

NAFLD in Adolescents and Young Adults With PCOS

NCT02506946
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
14 Years to 25 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 28, 2026, 6:26 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10

NCT02322086
View directory record Official record
Conditions
Psoriasis
Interventions
Topical Rose Bengal, 0.005%
Drug
Lead sponsor
Provectus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Miami, Florida • Chapel Hill, North Carolina • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 28, 2026, 6:26 AM EDT
Recruiting Phase 2 Interventional

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

NCT05003986
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
Interventions
Sparsentan
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Los Angeles, California • Wilmington, Delaware • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 28, 2026, 6:26 AM EDT
Completed Not applicable Interventional

Pilot for The Breast Cancer Endocrine Therapy Adherence (BETA) Trial

NCT02256670
View directory record Official record
Conditions
Breast Cancer
Interventions
Text Message Application
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Oct 28, 2026, 6:26 AM EDT
Active, not recruiting Phase 1 Interventional

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

NCT04930783
View directory record Official record
Conditions
Melanoma, Metastatic Melanoma
Interventions
CDX-301, NEOVAX, Nivolumab, Pembrolizumab
Drug · Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 28, 2026, 6:26 AM EDT
Completed No phase listed Observational

Role of Gene Variation in Effectiveness of Gleevec Treatment

NCT00342056
View directory record Official record
Conditions
Cancer, Breast Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 25, 2011 · Synced Oct 28, 2026, 6:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multi-Center Study to Evaluate the Performance of DermDx for Primary Care Physicians in the Detection of Skin Cancers

NCT06463860
View directory record Official record
Conditions
Skin Cancer
Interventions
DermDx
Device
Lead sponsor
MetaOptima Technology Inc.
Industry
Eligibility
Not listed
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
North Augusta, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 28, 2026, 6:26 AM EDT